Calimmune Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 3

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $416M

Calimmune General Information

Description

Developer of a gene modification and cell delivery technology based in Tucson, Arizona. The company's technology works by genetically modifying patients' own cells to shield and strengthen their immune systems and create enduring and life-long protection for individuals living with a broad range of debilitating and currently incurable diseases, enabling physicians to address the unique needs of individuals at different stages of HIV infection and with various treatment histories and offering effective and accessible products that have the power to restore health and improve lives.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Drug Discovery
Acquirer
Corporate Office
  • 5151 East Broadway Boulevard
  • Suite 1020
  • Tucson, AZ 85711
  • United States
+1 (310) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Calimmune Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 28-Aug-2017 $416M 000.00 00000 Completed Clinical Trials - Phase 2
8. Later Stage VC (Series C) 000.00 Completed Clinical Trials - Phase 2
7. Later Stage VC (Series B) 27-May-2015 000.00 000.00 00000 Completed Clinical Trials - Phase 2
6. Later Stage VC (Series A) 01-Dec-2013 000 00.000 0000 Completed Clinical Trials - Phase 2
5. Later Stage VC 01-Oct-2012 00.000 Completed Generating Revenue
4. Early Stage VC 16-Sep-2011 000 00.000 Completed Generating Revenue
3. Angel (individual) 01-Jun-2010 0000 0000 Completed Startup
2. Grant $8.28M Completed Startup
1. Spin-Off 01-Jan-2006 Completed Startup
To view Calimmune’s complete valuation and funding history, request access »

Calimmune Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 0,000,000 00.000000 00 000.0 000.0 00 000.0 0.000
Series A 0,000,000 00.000000 00 000.0 000.0 00 000 00.000
Series 4 000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series 3 00,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series 2 107,000 $0.001000 8% $4.94 $4.94 1x $4.94 0.85%
Series 1 188,136 $0.001000 8% $5 $5 1x $5 1.49%
To view Calimmune’s complete cap table history, request access »

Calimmune Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a gene modification and cell delivery technology based in Tucson, Arizona. The company's technology works b
Biotechnology
Tucson, AZ
3 As of 2023
000.00
00000 0000-00-00
000000&0 000.00

000000

in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
0000000000000
New York, NY
00 As of 0000
000.00
000000000 000.00

000000

ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercit
0000 000000000
Newark, CA
0 As of 0000
000.00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Calimmune Competitors (78)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Brainstorm Cell Therapeutics Corporation New York, NY 00 000.00 000000000 000.00
Cellerant Therapeutics Venture Capital-Backed Newark, CA 0 000.00 00000000000 000.00
Lineage Cell Therapeutics Corporation Carlsbad, CA 00 00000 000000000 00000
Aurora Biopharma Angel-Backed New York, NY 00000 0000000000 00000
Coave Therapeutics Venture Capital-Backed Paris, France 00 000.00 000000000000 000.00
You’re viewing 5 of 78 competitors. Get the full list »

Calimmune Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Calimmune Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
AbbVie Ventures Corporate Venture Capital Minority 000 0000 000000 0
Alexandria Venture Investments Venture Capital Minority 000 0000 000000 0
California Institute for Regenerative Medicine Government 000 0000 000000 0
Cycad Group Venture Capital Minority 000 0000 000000 0
DVI Equity Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Calimmune FAQs

  • When was Calimmune founded?

    Calimmune was founded in 2006.

  • Who is the founder of Calimmune?

    Inder Verma Ph.D, Irvin Chen Ph.D, Louis Breton, David Baltimore Ph.D, and Jon Faiz Kayyem Ph.D are the founders of Calimmune.

  • Where is Calimmune headquartered?

    Calimmune is headquartered in Tucson, AZ.

  • What is the size of Calimmune?

    Calimmune has 3 total employees.

  • What industry is Calimmune in?

    Calimmune’s primary industry is Biotechnology.

  • Is Calimmune a private or public company?

    Calimmune is a Private company.

  • What is the current valuation of Calimmune?

    The current valuation of Calimmune is 00000.

  • What is Calimmune’s current revenue?

    The current revenue for Calimmune is 00000.

  • How much funding has Calimmune raised over time?

    Calimmune has raised $19.9M.

  • Who are Calimmune’s investors?

    AbbVie Ventures, Alexandria Venture Investments, California Institute for Regenerative Medicine, Cycad Group, and DVI Equity Partners are 5 of 8 investors who have invested in Calimmune.

  • Who are Calimmune’s competitors?

    Brainstorm Cell Therapeutics, Cellerant Therapeutics, Lineage Cell Therapeutics, Aurora Biopharma, and Coave Therapeutics are some of the 78 competitors of Calimmune.

  • When was Calimmune acquired?

    Calimmune was acquired on 28-Aug-2017.

  • Who acquired Calimmune?

    Calimmune was acquired by CSL.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »